Transcode Therapeutics (RNAZ) Total Liabilities (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Total Liabilities for 7 consecutive years, with $12.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 497.15% year-over-year to $12.7 million; the trailing twelve-month figure through Jun 2026 stood at $12.7 million (up 497.15% YoY), and the FY2025 full-year result was $10.5 million, up 12.94% from the prior year.
• Total Liabilities held at $12.7 million in Q2 2026 per RNAZ's latest filing, from $12.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $12.7 million in Q2 2026 and bottomed at $1.7 million in Q2 2022.
• Historically, Total Liabilities has averaged $5.2 million across 5 years, with a median of $3.8 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities sank 76.43% in 2022, then surged 497.15% in 2026.
• Over 5 years, Total Liabilities stood at $4.3 million in 2022, then dropped by 18.83% to $3.5 million in 2023, then jumped by 163.91% to $9.3 million in 2024, then rose by 12.94% to $10.5 million in 2025, then increased by 20.28% to $12.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $12.7 million, $12.6 million, and $10.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.